This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Buy These 5 Low Leverage Stocks Amid Coronavirus-Led Sell Off
by Zacks Equity Research
This is a good time to go for safe stocks so that in the event of any further market turmoil the stockholders do not lose significantly. Stocks with low debt-to-equity ratio offer that safety.
Why Is Chemed (CHE) Down 28.5% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Grows Internationally, Hereditary Cancer Revenues Soft
by Zacks Equity Research
Myriad Genetics (MYGN) registers soft Hereditary Cancer, GeneSight, Vectra as well as Prenatal revenues in second-quarter fiscal 2020.
Medtronic to Boost Ventilator Capacity to Combat Coronavirus
by Zacks Equity Research
When all other major business segments of Medtronic (MDT) are facing recessionary hurdles, the company's latest move is anticipated to aid its Minimally Invasive Therapies Group business.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Here's Why You Should Add Chemed (CHE) to Your Portfolio Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on its strong segmental and international results in the fourth quarter of 2019.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from broad array of services and inorganic expansion. However, intense competition remains a woe.
Chemed (CHE) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Chemed (CHE) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Chemed (CHE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CHE) Outperforming Other Medical Stocks This Year?
How Chemed (CHE) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Chemed (CHE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Risk-Averse Investors May Buy These 5 Low Leverage Stocks
by Zacks Equity Research
Since a debt-free company is rare to find, measuring the debt level of a company is an important point of consideration while making an investment decision.
New Strong Buy Stocks for February 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
Chemed (CHE) Q4 Earnings & Revenues Beat Estimates, Margins Up
by Zacks Equity Research
Chemed's (CHE) fourth-quarter 2019 results reflect strong segmental performances.
Bet on These 5 Low Leverage Stocks to Escape a Debt Trap
by Zacks Equity Research
Exorbitant debt financing might lead to a corporation's bankruptcy in the worst-case scenario. Since a debt-free company is rare to find, we should focus on those carrying low debt levels
Zacks.com featured highlights include: Gibraltar Industries, Amedisys, Chevron, MDU Resources and Chemed
by Zacks Equity Research
Zacks.com featured highlights include: Gibraltar Industries, Amedisys, Chevron, MDU Resources and Chemed
Buy These 5 Low Leverage Stocks This Earnings Season
by Zacks Equity Research
With the Q4 reporting cycle gaining pace slowly, investors should look for stocks that are less debt-ridden compared to others instead of considering earnings growth only.
Icon PLC (ICLR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Icon PLC (ICLR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Invest in These 5 Low Leverage Stocks Before Q4 Earnings
by Zacks Equity Research
Companies displaying high earnings growth along with high leverage ratios should be avoided while making investment decisions. So, investors should select companies with low leverage.
Is Chemed (CHE) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Chemed (CHE) could produce exceptional returns because of its solid growth attributes.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Why Is Chemed (CHE) Up 7.7% Since Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?